作者
Kaitlyn M. Logan,Will Kaplan,Vladimir Simov,Hua Zhou,Derun Li,Luis Ángel Pérula de Torres,Gregori J. Morriello,John J. Acton,Barbara Pio,Yiheng Chen,Mitchell H. Keylor,Rebecca Johnson,Solomon D. Kattar,Ryan Chau,Xin Yan,Michael J. Ardolino,Cayetana Zárate,Karin M. Otte,Rachel L. Palte,Tina Xiong,Spencer E. McMinn,Shishi Lin,Santhosh Neelamkavil,Ping Liu,Jing Su,Laxminarayan G. Hegde,Janice D. Woodhouse,Lily Y. Moy,Paul J. Ciaccio,Jennifer Piesvaux,M. Zebisch,C. H. Henry,John Barker,Harold B. Wood,Matthew Kennedy,Erin F. DiMauro,Matthew Fell,Peter H. Fuller
摘要
Inhibition of leucine-rich repeat kinase 2 is a genetically supported mechanism for the treatment of Parkinson's disease. We previously disclosed the discovery of an indazole series lead that demonstrated both safety and translational risks. The safety risks were hypothesized to be of unknown origin, so structural diversity in subsequent chemical matter was prioritized. The translational risks were identified due to a low brain Kp
井哥儿
干净的铅笔
1257
我不爱池鱼
爱静静
热切菩萨
梦之凌云
从容芮
stuffmatter
pcr163
不懈奋进
Yziii
HEIKU
张三坟
薰硝壤
哎嘿
pluto
Leonardi
可言飞舞
shinysparrow
皖公网安备34019202002308
